Professional overview
Shi Yuankai is a Chief Physician and Professor in the Department of Medical Oncology at Cancer Hospital of Chinese Academy of Medical Sciences. Clinical work and research focus on medical treatment of solid tumors, autologous hematopoietic stem cell transplantation, and clinical trials of novel antitumor drugs with related translational research.
Department leadership
A department head is an organisational role. “Chief Physician” is a clinical rank; the two are listed separately.
Areas of focus
Background
- 1978Studied Japanese Medical Program, School of Medicine, China Medical University (6-year program)
- 1985Completed Master's degree in Oncology, China Medical University
- 1989Studied at Osaka University Graduate School of Medicine, Japan
- 1992Completed PhD in Oncology, Peking Union Medical College; began working at Cancer Hospital, Chinese Academy of Medical Sciences
- 1996Visiting scholar at University of Alabama at Birmingham
- 2000Visiting scholar at The University of Texas MD Anderson Cancer Center
- 2005Served as Director of the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences
- 2010Appointed Deputy Director of National Anticancer Drug Clinical Research Center
- 2012Appointed Director of Beijing Key Laboratory for Clinical Research of Antitumor Molecular Targeted Drugs
- 2015Appointed Deputy Director of National Cancer Center
Experience & recognition
- Led 38 research projects including National Science and Technology Support Program and 'Major New Drug Creation' Science and Technology Major Project
- Published 316 papers, including 58 SCI-indexed articles in journals such as The Lancet and The Lancet Oncology
- First or corresponding author of 218 papers
- Edited or translated 18 books; contributed to 15 others
- Chaired development of 9 national clinical guidelines and expert consensus documents including the 'Chinese Guidelines for Diagnosis and Treatment of Primary Lung Cancer (2015 Edition)' and 'Chinese Guidelines for Diagnosis and Treatment of Malignant Lymphoma (2015 Edition)'
- Recipient of State Council Special Allowance (1997)
- Second contributor to National Science and Technology Progress Award, First Class (2015)
- First contributor to six provincial or ministerial-level Science and Technology Progress Awards, First Class
Professional roles
- Vice President, Asian Organization for Clinical Oncology (AOCO)
- President, Chinese Medical Doctor Association (CMDA) Society of Oncologists
- Standing Committee Member, China Anti-Cancer Association (CACA)
- Director, CACA Professional Committee on Clinical Chemotherapy of Malignant Tumors
- Incoming Chair, CACA Lymphoma Professional Committee
- Vice Chair, CACA Cancer Rehabilitation Society
- Vice Chair, CACA Targeted Therapy Professional Committee
- Director, Chinese Pharmaceutical Association (CPA) Professional Committee on Anticancer Drugs
Frequently asked questions
What does Dr. Shi Yuankai specialize in?
Medical treatment of solid tumors including lung cancer, malignant lymphoma, gastrointestinal cancers, breast cancer, and malignant tumors of the urinary and male reproductive systems; autologous hematopoietic stem cell transplantation; clinical trials of novel antitumor drugs and related translational research
Which hospital and department is Dr. Shi Yuankai in?
Department of Medical Oncology at Cancer Hospital of Chinese Academy of Medical Sciences
Sources
- Compiled from public information about the doctor's clinical title, department and areas of focus, rewritten by Find China Doctors.
- Medical licence: National Health Commission doctor registry
Dr. Shi Yuankai has not reviewed this page.
